PL2187875T3 - Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu - Google Patents

Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu

Info

Publication number
PL2187875T3
PL2187875T3 PL07820536T PL07820536T PL2187875T3 PL 2187875 T3 PL2187875 T3 PL 2187875T3 PL 07820536 T PL07820536 T PL 07820536T PL 07820536 T PL07820536 T PL 07820536T PL 2187875 T3 PL2187875 T3 PL 2187875T3
Authority
PL
Poland
Prior art keywords
opioids
ethanol
influence
pharmaceutical composition
controlled release
Prior art date
Application number
PL07820536T
Other languages
English (en)
Inventor
Hans-Ulrich Petereit
Hema Ravishankar
Ashwini Samel
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of PL2187875T3 publication Critical patent/PL2187875T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07820536T 2007-09-21 2007-09-25 Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu PL2187875T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2136CH2007 2007-09-21
EP07820536A EP2187875B1 (en) 2007-09-21 2007-09-25 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
PCT/EP2007/060130 WO2009036811A1 (en) 2007-09-21 2007-09-25 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol

Publications (1)

Publication Number Publication Date
PL2187875T3 true PL2187875T3 (pl) 2013-01-31

Family

ID=39278276

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07820536T PL2187875T3 (pl) 2007-09-21 2007-09-25 Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu

Country Status (13)

Country Link
US (1) US9555006B2 (pl)
EP (1) EP2187875B1 (pl)
JP (1) JP5204846B2 (pl)
KR (1) KR101454056B1 (pl)
CN (1) CN101801356B (pl)
BR (1) BRPI0722042B8 (pl)
CA (1) CA2699224C (pl)
ES (1) ES2393805T3 (pl)
IL (1) IL203870A (pl)
MX (1) MX2010003036A (pl)
PL (1) PL2187875T3 (pl)
SI (1) SI2187875T1 (pl)
WO (1) WO2009036811A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923102C (en) 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
JP5453434B2 (ja) 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対する耐性を有するオピオイドではないｐＨ依存の制御放出の医薬組成物
US9757343B2 (en) * 2008-09-24 2017-09-12 Evonik Röhm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
WO2010057870A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
AU2009317279B2 (en) * 2008-11-18 2013-10-24 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
US9730899B2 (en) 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
US9877925B2 (en) 2010-05-14 2018-01-30 Ethypharm Alcohol-resistant oral pharmaceutical form
US20130059010A1 (en) * 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
CN103501768B (zh) * 2011-06-17 2016-11-09 赢创罗姆有限公司 具有抗乙醇影响抗性的抗胃酸的药物或营养组合物
MX353427B (es) 2011-06-17 2018-01-12 Evonik Roehm Gmbh Composicion de recubrimiento adecuada para formas de dosis farmaceuticas o nutraceuticas.
JP5832645B2 (ja) * 2011-06-17 2015-12-16 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ 医薬剤形又は栄養補助剤形に適したコーティング組成物
BR112015018895A2 (pt) * 2013-02-13 2017-07-18 Evonik Roehm Gmbh composição farmacêutica multiparticulada compreendendo uma multiplicidade de dois tipos de pelotas
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20150352140A1 (en) * 2014-06-07 2015-12-10 Api Intellectual Property Holdings, Llc Biomass-based dietary supplement
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN105769823A (zh) * 2014-12-24 2016-07-20 上海星泰医药科技有限公司 一种左旋盐酸米那普仑缓释胶囊及其制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR20200057019A (ko) 2017-09-14 2020-05-25 에보닉 오퍼레이션스 게엠베하 서방성 및 에탄올의 영향에 대한 내성을 갖는 중합체 및 투여 형태
EP3485879A1 (en) * 2017-11-17 2019-05-22 Maat Pharma Pharmaceutical oral formulation comrpsing bacteria
JP2021515778A (ja) 2018-03-09 2021-06-24 エボニック オペレーションズ ゲーエムベーハー エタノールの影響に対する耐性を有するポリマー混合物
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
US20260027062A1 (en) * 2022-03-03 2026-01-29 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
DE10211289A1 (de) * 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
CA2481091A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
CA2543689A1 (en) * 2003-10-31 2005-05-12 Hexal Ag Pharmaceutical actve-ingredient-containing formulation with coating
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug

Also Published As

Publication number Publication date
CA2699224C (en) 2014-12-16
CN101801356A (zh) 2010-08-11
KR101454056B1 (ko) 2014-10-27
ES2393805T3 (es) 2012-12-28
WO2009036811A1 (en) 2009-03-26
SI2187875T1 (sl) 2012-12-31
IL203870A (en) 2015-02-26
CN101801356B (zh) 2016-10-19
CA2699224A1 (en) 2009-03-26
MX2010003036A (es) 2010-04-09
BRPI0722042B8 (pt) 2022-07-05
US9555006B2 (en) 2017-01-31
KR20100063067A (ko) 2010-06-10
EP2187875B1 (en) 2012-09-05
US20100221324A1 (en) 2010-09-02
EP2187875A1 (en) 2010-05-26
JP2010539196A (ja) 2010-12-16
BRPI0722042B1 (pt) 2019-12-10
BRPI0722042A2 (pt) 2014-03-25
JP5204846B2 (ja) 2013-06-05

Similar Documents

Publication Publication Date Title
SI2187875T1 (sl) Od pH odvisen farmacevtski sestavek z nadzorovanim sproščanjem za ne-opioide z odpornostjo na vpliv etanola
IL211305A0 (en) Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
SI2187876T1 (sl) Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
IL211306A0 (en) Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
PT2345410T (pt) Composição farmacêutica para libertação modificada
HUS1800007I1 (hu) Gyógyászati készítmény
ZA200908019B (en) Controlled release pharmaceutical compositions for prolonged effect
IL214612A0 (en) Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
EP2265731A4 (en) METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
ZA201006793B (en) Oral controlled release tablet with reduced burst effect
GB2454567B (en) Anti-malarial pharmaceutical composition
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
IL208486A0 (en) Solid pharmaceutical formulation with delayed release
IL211886A0 (en) Solid pharmaceutical composition
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA201100871B (en) Solid pharmaceutical composition
HU0700485D0 (en) Pharmaceutical composition with controlled release containing tolperisone
PL2720683T3 (pl) Odporne żołądkowo kompozycje farmaceutyczne lub nutraceutyczne z odpornością na wpływ etanolu
ZA201001127B (en) Pharmaceutical formulation for extended release